Assorted news from the last week:
Thanks to a funding partnership among CAC2 Members, Spada Pediatric Sarcoma Foundation and Sam Day Foundation created the Ewing Sarcoma Research Fund with a starting corpus of $250,000 within the Beat Childhood Cancer Research Consortium.
For children with acute lymphoblastic leukemia (ALL), the type/dose of steroid seems not to be related to adverse psychological reactions (APRs) but may be associated with sleep problems, according to a review published in Psycho-Oncology.
AstraZeneca and MSD’s selumetinib has been recommended for conditional marketing authorisation in the European Union (EU) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged three years and above.
Upcoming Webinars and Online Opportunities:
The Coalition Against Childhood Cancer (CAC2) and the American Childhood Cancer Organization (ACCO) are pleased to invite you to a jointly convened online advocacy training meeting focused on State Cancer Action Plans–Primer on State Cancer Action Plans. Such plans, mandated by the Center for Disease Control (CDC), articulate the challenges and issues posed by cancer in each state and often include goals, objectives, and strategies to help inform and guide communities in the fight against cancer. Click the link above to register for this meeting to be held Tuesday, May 11, 2021, 7:00-8:30 pm ET.<\p>
CAC2 will host its May CAC2 All-Member webinar: Improving Time to Diagnosis for Pediatric and Young Adult Cancer Patients on May 12 at noon ET. The presentation will address the reasons why and solutions for detecting symptoms of cancer in children earlier in the diagnosis timeline. Speakers will include the founders of the UK’s Head Smart Program which has effectively addressed delayed diagnosis in children’s brain tumors.
Meeting of the Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee, May 11-12. On May 11, 2021, the subcommittee will discuss the development and successful implementation of the Pediatric Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) as a tool for eliciting the patient’s voice in oncology clinical trials to more accurately determine tolerability and toxicity of drugs under investigation. On May 12, 2021, the subcommittee will discuss real-world evidence (RWE) for regulatory use in pediatrics, real-world data (RWD) resources, and RWD and RWE to advance pediatric safety assessments of oncology drug products in children within the context of the FDA Framework for RWE. Potential data sources and publicly available platforms including those made possible through the development and implementation of the National Cancer Institute’s Childhood Cancer Data Initiative will be discussed. Link to join will be here two days before the meeting commences: https://www.fda.gov/advisory-committees/oncologic-drugs-advisory-committee/2021-meeting-materials-oncologic-drugs-advisory-committee.
CureSearch is pleased to continue the 2021 CureSearch Virtual Summit Series with the second session: Blurred Lines: Therapeutic vs Research-only Biopsies on May 14, 11:00-2:00 ET. This session will explore the concepts of “direct benefit” and “minimal risk” as they apply to biopsies and examine how new technologies and biomarkers are increasing the potential for therapeutic benefit with decreasing risk.